Cancer
Conditions
Interventions
The study will be carried out in two medical oncology wards at National Cancer Institute, Sri Lanka. The study will be carried out for the period of one year. Within the time period participant recru
Sponsors
Faculty of Medicine, University of Kelaniya
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients age 18 years old or above 2. Male and female patients 3. Patients diagnosed with cancer at any stage by an oncologist 4. Patients undergoing their 1st and 2nd cycles of chemotherapy
Exclusion criteria
Exclusion criteria: 1. Patients re-admitted during the study period 2. Patients with poor cognition with no caregiver to manage medicines 3. Patients who unable/unwilling to give informed written consent 4. Patients who already undergone 3rd cycle of chemotherapy onwards 5. Patients who have speech and communication disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement of quality of life (QOL) among patients with oncology as assessed by the mean score difference of EORTC QLQ-C30. QOL assessment will be done using standard EORTC QLQ-C30 (version 3.0) questionnaire. The QLQ-C30 questionnaire is a self-administered tool which comprises nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality-of-life scale. [At their baseline (before starting the chemotherapy cycle), middle of the cycle and at end of the cycle (1 week after the last cycle)] | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean Medication Appropriateness Index (MAI) will be compared between the control and intervention groups at the discharge in order to assess the appropriateness of discharge prescriptions. [Within hospital stay and at the discharge. ] Mean pain severity score will be measured at two intervals (on admission and at discharge) between both control and intervention groups in order to assess effectiveness of the treatment and further necessity of dose modifications of the prescribed medicines. [During hospital stay (admission and discharge of each patient)] The percentage of resolution of drug-related problems in both groups during the hospital stay. [During hospital stay] The percentage of occurrence of adverse drug reactions between the two groups during the hospital stay. [During hospital stay] Change in mean score of knowledge, attitude and practice on chemotherapy among both groups. [Before start and the end of the chemotherapy cycle.] The percentage of drug-related hospital re-admissions for six months follow-up period. [Six months from the recruitment.] The cost avoidance generated by pharmacist intervention will be interpreted as net cost-benefit and cost-benefit ratio. [During hospital stay] The mean satisfaction score of patients on ward-based pharmacy service will be measured at discharge. [At discharge of patient (During hospital stay). ] The percentage of acceptance of the ward-based pharmacy service by the doctors and nurses in the wards will be assessed at the baseline and at the end of the study. [At the beginning and the end of the project. ] | — |
Countries
Sri Lanka
Contacts
Public ContactDr. S.F. Jayamanne
Senior Lecturer
Outcome results
None listed